

Neovascular Age-Related Macular Degeneration

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (STAIRWAY)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03038880 CR39521

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This was a Phase II, multicenter, randomized, active comparator-controlled, 52-week study to investigate the efficacy, safety and pharmacokinetics of faricimab (RO6867461; RG7716) administered with extended dosing regimens in treatment-naïve participants with neovascular age related macular degeneration (nAMD). Only one eye was chosen as the study eye.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03038880 CR39521
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 50 Years

Healthy Volunteers
No